Skye Bioscience to Present at J.P. Morgan Healthcare Conference

Stock Information for Emerald Health Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Emerald Health Therapeutics Inc.

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity
Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity
Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025
Skye Bioscience to Participate in May Investment and Medical Conferences
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model
Skye Bioscience to Conduct Meetings at Piper Sandler Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.